article

Expert view: CRISPR screening: a powerful approach to drug discovery and development

Posted: 28 May 2020 | | No comments yet

CRISPR screening utilises the power and precision of CRISPR-Cas9 gene editing to reveal and validate novel drug targets or to study the underlying causes of disease.

It is also used to explore the effect of genetic mutations on drug activity, patient responsiveness and resistance.

This screening method uses CRISPR-Cas9 technology to modify and assess the function of thousands of genes in a single experiment, allowing researchers to quickly identify the genes relevant to a specific biological pathway. The most common approach, CRISPR KO (knockout) delivers complete gene inactivation, while CRISPRi (inactivate) and CRISPRa (activate) are used to target the endogenous gene at the transcriptional initiation site. These mechanisms can be combined to deliver dual loss-of-function or dual direction screening, conducted in either a pooled or arrayed format.

 

Reserve your FREE place

 


Are low affinity or poor TCR yields slowing you down?

Explore how CHO expression of soluble TCRs and TCR affinity maturation workflows via phage, serving as essential building blocks for early-stage TCR-TCE candidate generation.

22 October 2025 | 16:00 PM BST | FREE Webinar

Join Jiansheng Wu, Ph.D. to explore two integrated strategies:

  • High-titer CHO-based expression of sTCRs (~100 mg/L), enabling scalable and high-throughput production
  • Optimized phage display affinity maturation, improving TCR binding by up to ~10,000-fold

Whether you’re starting a new TCR program or optimizing an existing platform, this session will offer actionable strategies to accelerate discovery and improve candidate quality.

Register Now – It’s Free!

 

The speed with which CRISPR has enhanced therapeutic development is remarkable. This highly specific screening approach has enabled researchers to not only identify the compounds more likely to be successful in clinical trials but also stratify a patient population to determine which therapeutics will be most effective, helping to reduce the risk of trial failure. This technology can also be used to find the genes responsible for a particular cell behaviour, such as differentiation or required to engineer effective T cells for immunotherapies.

Horizon Discovery has more than 10 years’ of experience working in gene engineering and leads the way in offering a broad range of CRISPR screening services – from initial design and cell-line selection to bioinformatic analysis of the screen results. The breadth of our platforms enables us to design custom solutions for almost any screening requirement and cellular background, including primary cancer lines and primary immune cells. We are actively engaged with biopharmaceutical companies, providing services that save time and resources while they navigate towards a successful therapeutic.

Related organisations

Leave a Reply

Your email address will not be published. Required fields are marked *